Treatment of HIV infection with the CCR5 antagonist maraviroc.


IMPORTANCE OF THE FIELD The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of the currently available antiretroviral drugs. New drug classes are thus required. Maraviroc is the first chemokine receptor 5 antagonist approved for use in treatment experienced HIV patients with a R5-tropic virus. AREAS COVERED… (More)
DOI: 10.1517/14656561003801081